Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT2A receptors: functional receptor-binding and in vivo electrophysiological studies

Abstract

These results support a partial agonist activity for aripiprazole at 5-HT(1A) receptors in vitro and in vivo, and suggest important interactions with other 5-HT-receptor subtypes. This receptor activity profile may contribute to the antipsychotic activity of aripiprazole in humans.

Treating Bipolar Disorder in the Primary Care Setting

“…[84][85][86][87][88] A partial agonist exhibits lower activity at the target receptor than would occur with a full agonist and therefore has the capability to treat behavioral states that include both excessive and deficient neurotransmitter activity. Theoretically, therefore, aripiprazole has the ability to reduce dopamine transmission in states of dopamine excess (eg, bipolar mania) and to increase dopamine transmission in states of dopamine deficiency.…”

Evaluating The Antidepressant Efficacy of Aripiprazole Using a Chronic Mild Stress Model: An Experimental Study

“…It is also a n e w g e n e r a t i o n , d o p a m i n e -b a l a n c i n g antipsychotic drug, which is a partial agonist for dopamine D 2 and D 3 , serotonin 5-HT 1A , 5-HT 2C and 5-HT 7 receptors, and antagonist for 5-HT 2A and 5-HT 6 receptors [1][2][3][4] . It is considered that partial D 2 agonism stabilizes dopaminergic nerve communication in the mesolimbic and m e s o c o r t i c a l p a t h w a y s 5 .…”

“…Bu gruba KHS uygulanmadan serum fizyolojik plasebo olarak verildi. İkinci gruba kronik hafif stres (KHS) ile birlikte aripiprazol (2.5mg/kg), 3. gruba KHS ile birlikte essitalopram (10mg/kg), 4. gruba KHS ile birlikte plasebo (serum fizyolojik) verildi.…”

Development of Gummi Drugs of Aripiprazole as Hospital Formulations

“…[16][17][18][19][20] It is prescribed for depression as well as the symptoms of depression. Uncoated tablets, ODTs, oral solutions (OS), and oral powders (PW) of aripiprazole have been developed and marketed, thereby enabling various choices for oral administration.…”